Description

Venous Thrombus Embolism (VTE), the general term for deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a grave threat to those patients who have accepted Total Hip Replacement (THR) or Total Knee Replacement (TKR). It is estimated that blood clots form in 50% of THR patients and 60% of TKR patients.

View Full Report at: http://www.marketresearchreports.biz/analysis/289109

According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Bayer/ Johnson & Johnson. In Oct. 2008, rivaroxaban was approved to come into the Canada and the EU markete under the trade name of Xarelto while on Jul. 1, 2011, it was approved by FDA to enter the American market. Rivaroxaban has been approved by more than 100 countries in the world and succeeded in entering over 75 countries. According to the statistics of Bayer/ Johnson & Johnson, the sales value of rivaroxaban in the world exceeded USD 2.124 billion in 2013, increasing by 219% compared with last year.

After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter half of 2009, it develops fast with annual sales rising from less than CNY 20 million in 2010 to CNY 140 million in 2014 and CAGR reaching up to over 70% during the period of 2010-2014. Currently, the rivaroxaban market in China has been monopolized by Bayer. The price of rivaroxaban is relatively high for it is imported. The price range of 10 mg rivaroxaban (tablets, 5 tab. per package) is 364.20-388.68 CNY/package in sample hospitals with cities differing slightly in its price. Some Chinese enterprises have been developing the generic drugs of rivaroxaban. And it is estimated that the market size of rivaroxaban in China will keep expanding in the next few years.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289109

Readers can get at least the following information through this report:

market share of manufacturers of rivaroxaban in Chinese hospitals
price of rivaroxaban in Chinese hospitals
major manufacturers of rivaroxaban
share of different dosage forms of rivaroxaban in Chinese hospitals
market outlook of rivaroxaban in China

The author suggests the following groups of people purchase this report:

manufacturers of antithrombotic agents
investors/ research institutions interested in Chinese medicine market

Table of Content

1 Related Concepts of Rivaroxaban
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Rivaroxaban in China
2.1 Patent and Approval Status of Rivaroxaban in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Rivaroxaban in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz


Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]